Our goal was to provide comprehensive data on the effectiveness of ketamine in refractory status epilepticus (RSE) and to describe the potential consequences of long-term ketamine infusion. Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, blocks excitatory pathways contributing to ongoing seizure. While ketamine use is standard in anaesthetic induction, no definitive protocol exists for its use in RSE, and little is known about its adverse effects in long-term, high-dose administration. We present two cases of RSE that responded rapidly to ketamine infusion, both with fatal outcomes secondary to metabolic acidosis and cardiovascular collapse. We performed a systematic review of the application and consequences of ketamine use in RSE. PubMed, Ovid, MEDLINE and PMC were searched for articles describing ketamine treatment for RSE according to a predetermined search strategy and inclusion criteria. The systematic review revealed wide discrepancies in ketamine dosing (infusion maintenance dose range 0.0075-10.5 mg/kg/hour), but good outcomes in medically managed RSE (75% of studies reported moderate or complete seizure control in adults, 62.5% in paediatrics). Additionally, literature review elucidated a potentially causal relationship between prolonged ketamine infusion and both cardiovascular and metabolic dysregulation. Ketamine is effective in RSE by antagonising excitotoxic NMDA receptors. However, there is high variability in ketamine dosing and scarce data on its safety in long-term infusion. Metabolic acidosis and haemodynamic instability associated with the use of long-term, high-dose ketamine infusions must be of concern to clinicians administering ketamine to critically ill patients.
Status epilepticus (SE) is a neurological emergency defined by the International League Against Epilepsy as a prolonged seizure that is thought to have overcome termination mechanisms at a certain timepoint since seizure onset (t 1 ) and has persisted past a second timepoint (t 2 ) after which there is cortical damage. This definition encompasses all subtypes of SE and addresses approximate timepoints for each subtype: tonic-clonic (t 1 = 5 minutes, t 2 = 30 minutes), focal (t 1 = 10 minutes, t 2 = 60 minutes) and absence (t 1 = 10 to 15 minutes, t 2 = unknown) 1 . Refractory status epilepticus (RSE) is SE that endures beyond timepoint t 2 despite firstand second-line anti-epileptic drug (AED) treatment, and therefore is an inherently neurotoxic process 1 . Furthermore, we additionally define super-refractory status epilepticus as RSE that persists for more than 24 hours after the addition of a third-line agent, usually a general anaesthetic 2, 3 . These definitions and subclassifications of SE are meant to encourage early and aggressive intervention with multiple AEDs, especially in refractory seizures, to limit neurotoxicity 4 . The incidence of RSE and super-refractory status epilepticus is 40% in patients initially presenting with SE, with mortality rates approaching 50% 2, 5, 6 . The managing physician's goal is to rapidly attenuate seizure activity as the duration of SE positively correlates with poor functional outcomes 7 . Current guidelines for SE management target the activation of inhibitory gamma-aminobutyric acid-A (GABA-A) receptors. However, studies have shown that prolonged seizure activity affects the ratio of expression of inhibitory versus excitatory receptors on the neuronal cell membrane. These biomolecular changes are thought to explain the inefficacy of GABA-A agonists in RSE: seizures become self-sustaining, progress independently of their initial trigger and develop a time-dependent pharmacoresistance to benzodiazepines and other GABA-A modulators 8 . In 2005, researchers first identified a decrease in GABA-A . After one hour of lithium-pilocarpine-induced SE, dentate granule cells showed a 50% reduction in GABA-A receptors per synapse. Subsequent work by the same group identified a parallel relocation of N-methyl D-aspartate (NMDA) receptor subunits from the cytoplasm to the cell surface. Patch-clamping of these cells showed a corresponding increase in NMDA-mediated excitatory postsynaptic currents. Statistical analysis estimated a 38% increase in functional post-synaptic NMDA receptors in the hippocampus during SE 10 . This augmented NMDA-mediated excitation potential, coupled with decreased GABAergic inhibitory signalling, represents our current understanding of the mechanism for seizure maintenance in SE and, furthermore, may explain the excitotoxicity associated with prolonged seizure. This experimental work, corroborated by numerous animal studies, provides the rationale for using NMDA receptor antagonists (such as ketamine) in RSE [11] [12] [13] [14] [15] . The NMDA receptor is a non-specific cation channel that mediates glutamatergic neurotransmission and has NMDA and phencyclidine binding sites 16 . When the cell membrane is depolarised and the channel protein is activated by glutamate or glycine at the NMDA binding site, a magnesium ion that blocks the internal aspect of the channel at rest is dislodged. Influx of sodium and calcium through the channel further depolarises the membrane and propagates excitatory impulses.
Ketamine, a non-competitive antagonist of the NMDA receptor, inhibits the transmission of excitatory potentials by inactivating the NMDA receptor at the phencyclidine binding site and is thought to have both neuroprotective and anti-inflammatory effects within the context of seizures [17] [18] [19] [20] [21] [22] [23] . In 1995, Fujikawa et al demonstrated the neuroprotective qualities of ketamine in a rat model of SE. Subjects that received intraperitoneal ketamine showed a significantly decreased percentage of irreversibly damaged neurons compared to controls 18 . Stewart et al demonstrated the behavioural correlate to Fujikawa et al's research by showing that rat models of SE receiving early ketamine treatment performed equitably in both learning-related tasks of conditioned taste aversion and in a paradigm of fearconditioned analgesia compared to non-epileptic controls 19 . At the molecular level, ketamine-mediated NMDA antagonism inhibits elongation factor 2 kinase downstream and indirectly enhances brain-derived neurotrophic factor synthesis, providing a biochemical explanation for the improved maintenance of memory in these SE murine models [20] [21] [22] [23] . Anaesthetists have long valued the cardio-stimulatory properties of ketamine that markedly contrast with the cardiovascular profiles of most alternative anaesthetic agents [24] [25] [26] . In the early 1970s, Tweed et al studied the cardiovascular effects of intravenous ketamine in twelve patients undergoing cardiac catheterisation 24 . There was an increase in the cardiac index of patients in all subject groups ranging between 26% and 29%, which was thought to be predominantly due to an increase in myocardial contractility. Soon after, Johnstone published data in 1976 clarifying ketamine's role in increasing systemic vascular resistance in human subjects. Ketamine must work to cause vasoconstriction by altering calcium flux in arterial smooth muscle since immediate reversal of ketamine-induced hypertension was consistently achievable with verapamil (an L-type calcium channel blocker) 25 . Ketamine has also demonstrated anti-inflammatory effects both in vitro and in the clinical setting, and this property of ketamine may contribute directly to its analgesic effects 27, 28 . Though the exact mechanisms for its immunomodulatory activity remain unclear, ketamine is known to lower serum levels of interleukin-6, tumour necrosis factor-alpha, inducible nitric oxide synthase and C-reactive protein and to attenuate the activity of the nuclear factor-�B pathway, a prototypical pro-inflammatory signalling pathway responsible for the expression of various cytokines 29 . Anaesthetists and surgeons have observed that the neuroprotective, cardiostimulatory and anti-inflammatory properties of ketamine work together to reduce the incidence of postoperative cognitive dysfunction, particularly following cardiac surgery where there exists a high risk for this complication 30 .
Neurointensivists can therefore extrapolate that repurposing ketamine as an anticonvulsive agent may not only yield better control of intractable seizures due to its antagonism of the NMDA receptor, but also might reduce the high mortality and functional morbidity inherent to RSE.
Case reports
Informed consent concerning publication of unique case presentations was obtained from the primary health care proxies of the patients described herein as original case reports.
Case 1
A 41-year-old man with a lifelong history of epilepsy presented from a long-term care facility where aspiration pneumonia had triggered a seizure exacerbation leading to SE. SE had been ongoing for nearly a week prior to presentation. His seizure disorder was initially diagnosed at age three and imaging had shown a focus of cortical dysplasia alongside a tumour of unknown pathology. After surgical resection of the lesion, he was left with residual leftsided weakness, a minor learning disability and persistent seizure. His seizure disorder was managed with multiple AED regimens that had included phenobarbitone, valproic acid, clonazepam, nitrazepam, clobazam, gabapentin, topiramate, phenytoin, carbamazepine, levetiracetam, sulthiame, and lacosamide. His typical seizure semiology was a focal seizure (without dyscognitive features) with left facial twitching and spread to the left upper and/or lower extremity, rarely complicated by loss of awareness. On this presentation, he was first seen at an outside hospital where electroencephalography (EEG) showed a seizure rate of approximately 100 seizures per 24-hour period. He was intubated, started on midazolam and propofol infusions and transferred to our Neurosciences Intensive Care Unit for further management.
On initial exam, the patient's mental status was waxing and waning with a Glasgow Coma Scale score of 9. He had minimal strength in his left arm and his left leg was without spontaneous movement. Non-contrast head computed tomography (CT) was negative for acute intracranial pathology. His metabolic panel showed no electrolyte disturbances, but serum levels of phenytoin and valproic acid were subtherapeutic. Despite aggressive initial management with multiple AEDs including fosphenytoin, valproic acid, carbamazepine, levetiracetam, lacosamide, clobazam, and continuous infusions of midazolam and propofol, seizures persisted ( Figure 1 ). On hospital day 16, after recently being weaned from midazolam and propofol, newly aggressive seizure activity prompted the initiation of ketamine as an adjunct therapy. A bolus of 3 mg/kg of ketamine was given, followed by a maintenance infusion of 1.5 mg/kg/hour with the goal of up-titrating by 0.5 mg/kg/hour until the EEG showed burst suppression. Within 12 hours of starting ketamine, total electroencephalographic suppression was achieved. Two days later, however, focal seizure activity recurred, prompting an up-titration of ketamine to 4 mg/kg/hour. On hospital day 22 (ketamine day seven), the patient developed new bibasilar opacities on chest X-ray, sudden-onset hypothermia, an increased vasopressor requirement and a hyperchloraemic metabolic acidosisthought initially to be a topiramate-induced proximal renal tubular acidosis. Topiramate was discontinued and the ketamine dose was halved. Given the focality of his seizures, the patient was briefly considered for epilepsy surgery, but continued haemodynamic instability limited his candidacy for such intervention.
The patient's seizures again resolved after three days of ketamine at 3 to 4 mg/kg/hour on hospital day 25 (ketamine day ten), but he developed a lactic acidosis (pH 7.2, lactate 2.4 mmol/l). Possible aetiologies included increased doses of ketamine or midazolam versus worsening sepsis, and as a precaution, ketamine was down-titrated over two days. Continuous seizure activity returned with increased vasopressor requirements, hypervolaemic hyponatraemia, persistent lactic acidosis, thrombocytopenia (attributed to the supratherapeutic valproic acid level), and eventually, the patient required a unit each of red blood cells and platelets. Salvage therapy with a lidocaine infusion and the addition of more AEDs including gabapentin, clobazam and oxcarbazepine all failed. On hospital day 36, midazolam and propofol infusions were restarted, but seizure cessation was not achieved until the re-initiation of ketamine at 1.8 mg/kg/ hour, up-titrated by 1.8 mg/kg/hour every five minutes until burst suppression was observed at 7.2 mg/kg/hour. However, after two days of complete EEG suppression, the patient went into pulseless electrical activity arrest and despite advanced cardiac life support and administration of epinephrine (adrenaline) and bicarbonate, the patient expired.
Case 2
A 28-year-old man with a lifelong history of treatmentresistant focal epilepsy presented to the neurology service when his postoperative course after implantation of a responsive neurostimulation device was complicated by SE (suspected to be due to missed doses of anti-epileptics). He had a complicated seizure history starting at age four when he was first diagnosed with absence seizures. He had been medically managed until his seizure disorder was exacerbated at age seven by Lyme disease, which led to gelastic and tonic seizure semiology with occasional drop attacks. He underwent resection of a right frontotemporal focus, which decreased his seizure frequency, but remained refractory to further medical management including ketogenic diet, felbamate, topiramate, and tiagabine. At age 14 years he underwent a series of aggressive cortical resections with pathology that revealed Chaslin-type gliosis, chronic mild meningitis and mild cortical dysplasia. He subsequently continued to experience frequent seizures and multiple episodes of SE. His seizure semiology on presentation was focal seizure with dyscognitive features that secondarily generalised, preceded by an aura of epigastric rising and tonic left arm and neck extension. At baseline, he was cognitively impaired with decreased attention.
On admission to the Neurosciences Intensive Care Unit, the patient had extreme rightward gaze deviation with continuous tremor in all extremities. He received lorazepam, levetiracetam, and phenytoin in addition to his home antiepileptics, eslicarbazepine, phenobarbital, topiramate, clobazam and vigabatrin ( Figure 2 ). Persistent seizure activity prompted intubation and administration of highdose propofol and fentanyl. On hospital day nine, despite escalating doses of propofol and trials of a ketogenic diet and clonazepam, the EEG continued to show SE. Midazolam (2.9 mg/kg/hour) and ketamine (5 mg/kg/hour) infusions were promptly initiated, rapidly resulting in burst suppression.
The EEG remained burst suppressed for three days (maximum dose ketamine 7 mg/kg/hour, midazolam 3.1 mg/ kg/hour) after which the patient was weaned off both ketamine and midazolam over two days. Seizures promptly returned and the previous regimen was restarted on hospital day 13 (ketamine 4 mg/kg/hour, midazolam 4 mg/ kg/hour). Additionally, the recently-implanted responsive neurostimulation device was activated. He was also enrolled in a clinical trial (SAGE-547) investigating allopregnanolone (an allosteric modulator of the GABA-A receptor) versus placebo for super-refractory status epilepticus and started receiving the investigation drug daily. The patient thereafter remained seizure-free for the rest of his course. On hospital day 16 (ketamine and midazolam day four), the patient developed a new right bundle branch block, bradycardia, hypotension requiring vasopressors, and a severe anion gap metabolic acidosis with hyperchloraemia and elevated lactate. Differential diagnoses included propofol infusion syndrome or bowel ischaemia considering a recently diagnosed ileus. Propofol was immediately discontinued and ketamine and midazolam infusions were stopped within 36 hours. Nevertheless, on hospital day 17, the patient succumbed to cardiac arrest with peri-mortem blood test results notable for worsening metabolic acidosis, with rising lactate, potassium and creatinine.
Methods
A systematic review was performed as described below using the methodology for the collection and reporting of data outlined in the Preferred Reporting Items for Systematic Reviewers (PRISMA) statement 31 .
Search question, primary outcome, inclusion and exclusion criteria
The question posed for systematic review was: what is the effectiveness of ketamine in the management of RSE? All types of peer-reviewed articles, including case reports, case series, cohort studies, and systematic reviews, based on human subjects and published in the English language, were included.
The primary outcome measure was control of seizure activity after ketamine treatment as seen clinically or verified by EEG, further defined as complete control (total remission of seizures indefinitely in all patients), moderate control (total remission of seizures in 50% or more of patients), mild control (total remission of seizures in less than 50% of patients), poor control (partial remission of seizures for a finite period of time in all patients), and failed (seizures persisted despite treatment). This qualitative symptomatic response grading was used given the heterogeneous nature of the treatment response data reported across studies. Secondary outcome measures included an examination of the loading doses, maintenance doses, and overall duration of ketamine infusion required to achieve seizure control, a review of the time to initiation of ketamine treatment after a diagnosis of SE was made, and a more qualitative review of the incidence and spectrum of adverse events associated with ketamine treatment.
Studies eligible for inclusion met the following criteria: 1) patients had a definitive diagnosis of SE, 2) patients received ketamine as part of their anti-epileptic regimen, and 3) seizure response after ketamine administration was clearly documented. Exclusion criteria were: 1) use of nonhuman subjects, 2) non-English publications, and 3) meeting abstracts, unpublished data or communications.
Search strategy and study selection
PubMed, Ovid MEDLINE and PMC were searched using a defined search strategy adjusted for each database. Reference lists of all publications were additionally reviewed for relevant studies on the use of ketamine in RSE.
A two-step review of all articles returned by our search strategy was performed. First, two reviewers independently screened all titles, abstracts and full text of the returned articles to decide if they met the inclusion criteria. Second, any discrepancies between the two reviewers was resolved by discussion. The search process uncovered 21 peerreviewed articles comprised of case reports, case series, cohort studies, and systematic reviews published between 1996 and 2017.
Data collection and quality assessment
Data was extracted independently from the selected articles by two reviewers and stored in an electronic database. Data fields included study design, patient age range, ketamine route of administration, ketamine bolus dose range, ketamine maintenance dose range, time between diagnosis of SE and initiation of ketamine treatment, total duration of ketamine treatment, time to clinical response to ketamine treatment, the primary outcome as defined above, and incidence of adverse events suspected to be related to ketamine treatment.
The study quality of case reports and case series was assessed according to the CARE guidelines 32 . Given the heterogeneity of styles of case reports, those studies that met at least ten out of 13 CARE criteria (77%) were considered high-quality studies and were included in our review. Additionally, the study quality of systematic reviews was assessed according to the PRISMA statement and associated checklist 31 . Studies that reported a complete PRISMA checklist were deemed high-quality studies and were included in our review. Lastly, the study quality of cohort studies was assessed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement 33 . Studies that reported a complete STROBE checklist for cohort studies were assessed as high-quality studies and were included in our review.
Results
In this systematic search of the literature, we evaluated the efficacy of ketamine in RSE across both adult and paediatric patient populations and secondarily, given that there currently exists no standard protocol for this application of ketamine, examined how variations in dosing contributed to adverse events. While ketamine has neuroprotective effects in adults, paediatric patients, with developing brains undergoing continuous neurogenesis, are thought to be particularly susceptible to neurotoxicity 29, 30, 34, 35 . Paradoxically, the incidence of ketamine use in paediatric patients with RSE is steadily increasing despite two sets of recently published recommendations on RSE management; one listing ketamine a fifth-line agent and the second, an international survey of RSE experts, not mentioning ketamine at all [36] [37] [38] . Given the appreciable differences in incidence of use, dosing strategies, and potential adverse events between adult and paediatric patients, we separated our analysis of adult and paediatric studies.
The results of our search strategy is summarised in Figure  3 . Overall, 5,232 articles were identified. After application of inclusion and exclusion criteria and accounting for duplication of references, only 21 peer-reviewed articles were eligible for inclusion in our review. Of these 21 articles, there were ten case reports, nine case series, one cohort study and one systematic review.
The literature on ketamine treatment for RSE in adults includes eight case reports, seven retrospective case series and a single systematic review (Table 1) 15, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Of these 16 studies, nine (56%) report complete seizure control in all patients treated with ketamine. Moreover, three studies (19%) report outcomes indicating moderate control, in which more than 50% of patients studied achieved complete remission of seizures, one study (6%) cites mild control (less than 50% of patients with complete seizure control), two Yo, years old; IV, intravenous; PO, per os/by mouth; BID, twice daily; EEG, electroencephalography; n/a, not available; s, seconds; min, minutes; h, hours; d, days; mo, months; mg, milligrams; kg, kilograms; Hz, Hertz. *All reported dosing converted to mg/kg/h. # Gaspard report is a multicentre retrospective case series including adult and paediatric cases, dosing data for which was not separated within the body of the paper.
##
Sabharwal is a retrospective case series including adult and paediatric cases, data for which is not separated within the body of the paper. studies (13%) document poor control (partial remission for a finite period), and one study (6%) describes failure to respond to ketamine. Concerning dosing strategies, 73% of studies used bolus dosing of ketamine, ranging from 0.5 to 5 mg/ kg, which either functioned as the entire treatment protocol or as loading doses prior to initiating continuous infusions. Maintenance infusion doses ranged from 0.05 to 10.5 mg/ kg/hour, and two studies used enteral dosing (50 to 250 mg twice daily). Duration of ketamine infusion ranged from two hours to 29 days. Initiation of ketamine treatment universally started after the administration of multiple anti-epileptic agents. Time to ketamine treatment after an SE diagnosis ranged from under 24 hours to 140 days. Time to clinical or EEG response to ketamine ranged from immediate response to 28 days. Of note, 70% of studies reported seizure control in under 48 hours of ketamine treatment. Adverse events included one report of cerebellar dysfunction, one report of transient hypertension, two reports of supraventricular tachyarrhythmia, and one report of severe metabolic acidosis after high-dose ketamine infusion co-administered with midazolam 15, 41, 48 . SE is the most common neurological emergency in paediatrics and affects between 17 to 23 per 100,000 children each year, of whom 25% to 45% progress to RSE 37, 54 . The literature on ketamine in paediatric RSE includes two case reports, four case series, one cohort study, and one Yo, years old; IV, intravenous; PO, per os/by mouth; EEG, electroencephalography; n/a, not available; s, seconds; min, minutes; h, hours; d, days; wk, weeks; mo, months; mg, milligrams; kg, kilograms. *All reported dosing converted to mg/kg/h #Gaspard report is a multicentre retrospective case series including adult and paediatric cases, dosing data for which was not separated within the body of the paper. ##Sabharwal report is a retrospective case series including adult and paediatric cases, data for which was not separated within the body of the paper. ###Keros is a retrospective cohort study that specifically reviewed cases of co-administration of ketamine and pentobarbital.
systematic review as shown in Table 2 36, 48, 49, 51, [55] [56] [57] [58] . Of these eight studies, one (12.5%) reported complete control of seizure activity in all patients, four (50%) described moderate control, one (12.5%) reported mild control and two studies (25%) reported poor seizure control (none reported failure of treatment response). The paediatric literature yields the widest discrepancies in dosing strategies. Loading bolus doses ranged from 0.002 to 5 mg/kg and continuous infusions ranged from 0.0075 to 10.5 mg/kg/h. One study used enteral dosing at 0.0625 mg/kg/h 56 . Duration of ketamine infusion ranged from six hours to 287 days, perhaps reflecting an inherently more refractory nature of paediatric presentations of SE (adult range was two hours to 29 days) 36, 48, 49, 51, [55] [56] [57] [58] . Initiation of ketamine treatment ranged from five hours to 82 days after diagnosis of SE. Adverse effects in the paediatric literature generally reflect that of the adult literature and additionally include one case of aggressive behaviour and four cases of hypersalivation and transient elevation in liver enzymes 48, 56, 57 .
Discussion

Timing of ketamine administration
The goal in RSE management is to preserve cortical function and reduce morbidity and mortality related to prolonged seizure. Poor functional outcomes in RSE have been reported at rates of over 75% and are highly correlated with duration of seizure 7, 59 . Given our knowledge of the biomolecular changes at the neuronal membrane in prolonged seizure and the associated early onset of pharmacoresistance to GABAergic drugs, there is clear rationale for considering earlier initiation of ketamine in RSE treatment protocols [8] [9] [10] [11] [12] [13] [14] [15] . Ketamine's currently limited role as a salvage treatment is attributable to physician inexperience with dosing ketamine, ketamine's ill-defined side-effect profile in prolonged use, and the general scarcity of literature on its use in refractory seizures.
Per our systematic review, there is some limited evidence supporting better clinical outcomes and more prompt seizure control with early administration of ketamine in SE. A 2012 case report describes the use of ketamine as a fifthline agent in RSE after phenytoin, midazolam, propofol, and levetiracetam failed to suppress ongoing seizure activity 45 . In this case, ketamine was given within six hours of seizure onset and quickly resulted in complete suppression of seizure activity on EEG 45 . A 2017 case report also describes using ketamine within the first 24 hours of RSE with a similarly prompt treatment response 53 . In both of our cases, ketamine infusion was not introduced for several weeks (after trials of multiple AEDs), but after initiation, achieved burst suppression on EEG within 12 hours.
Adverse effects
Identifying side-effects specifically associated with ketamine is difficult since it is typically administered in conjunction with multiple other anti-epileptic agents. The wide range in dosing, timing of administration and duration of treatment across the literature further obscures a causal relationship between ketamine and any given adverse event. While many articles reviewed herein enthusiastically describe ketamine's positive safety profile, a handful of authors describe experiences of similar adverse events, including agitation, hypersalivation, hepatotoxicity, cardiac dysrhythmia, and severe metabolic acidosis 15, 41, 48, 56, 57 . Ketamine is well-described in the anaesthesia literature as possessing both indirect stimulatory effects and direct depressant effects on the cardiovascular system. The indirect stimulatory effects are mediated by the release of endogenous catecholamines, which cause bronchodilation and increases in heart rate and systemic vascular resistance. This cardiopulmonary stimulatory quality of ketamine stands in stark contrast to the reliably hypotensive effect of most other anaesthetic agents and has made ketamine many anaesthetists' drug of choice for induction [60] [61] [62] . Ketamine has even come to be preferred over etomidate (another anaesthetic agent known to maintain cardiovascular stability) since it has been established that etomidate inhibits adrenal corticosteroid biosynthesis-a finding linked to increased mortality in septic patients 63 . Paradoxically, however, ketamine also has a direct negative inotropic effect on the myocardium that involves the disruption of calcium currents in the cardiac myocyte, prolonging the action potential 64 . A given patient's response to ketamine induction can be thought of as a product of ketamine's two competing haemodynamic effects, of which the dominant effect is determined by pre-infusion catecholamine stores. In other words, ketamine's direct negative inotropic properties predominate when endogenous catecholamines have been depleted by stress or chronic illness 65, 66 . While rare, there are case reports of cardiovascular collapse immediately after ketamine administration at doses of 2-2.4 mg/kg in critically ill patients 67 . Given that both of our patients suffered from cardiovascular collapse after prolonged hospitalisations involving deterioration to an acidotic state, it is conceivable that ketamine's negative inotropic effects dominated the drug's pharmacodynamics and contributed to clinical decline. In Case 1, the patient had just restarted ketamine infusion at 7.2 mg/kg/hour, one of the highest reported infusion doses for SE, two days prior to succumbing to cardiac arrest. In Case 2, while the patient was not receiving ketamine at the time of death, he had been weaned off ketamine a few days prior due to an acute presentation of right bundle branch block, hypotension, and bradycardia.
Cumulative experience is fundamental to defining the safety profile of the prolonged intravenous administration of any pharmacologic agent. For example, years of administering intravenous lorazepam and diazepam, which previously held reputations for safety, exposed the now well-characterised propylene glycol toxicity from the solvent of these two benzodiazepines [68] [69] [70] . Long-term etomidate for sedation was found to be associated with a large increase in mortality secondary to drug-induced adrenal insufficiency 71 . These findings have led to consensus on strict dosing guidelines for both etomidate and the benzodiazepines [71] [72] [73] . Perhaps most relevant to the current guidelines for SE management is the complication of propofol-related infusion syndrome, a constellation of bradycardia, anion gap metabolic acidosis, rhabdomyolysis, hepatomegaly and lipaemia that presents only after extended, high-dose use 74, 75 . Given the relative paucity of experience with long-term ketamine infusion, more weight should be ascribed to the adverse events reported in the articles we have reviewed. Further research should focus on obtaining more anecdotal evidence for comparison, or preferably, conducting prospective studies evaluating the safety of prolonged ketamine treatment.
In our two cases, a severe metabolic acidosis developed during prolonged ketamine treatment, notably with co-administration of midazolam. Gaspard et al describes a ketamine infusion-related acidosis that presented much like propofol-related infusion syndrome after four days of high-dose ketamine (4.5 mg/kg/hour) and midazolam (2.5 mg/kg/hour) 48 . In Case 1, we observed a severe non-anion gap hyperchloraemic metabolic acidosis after six days of continuous co-administration of ketamine (1.5 to 4 mg/kg/ hour) and midazolam (0.6 to 2.8 mg/kg/hour). In Case 2, a hyperchloraemic metabolic acidosis, although with an anion gap, developed after four days of midazolam (2 to 4 mg/kg/ hour) and ketamine (3 to 4 mg/kg/hour) treatments. In both cases, down-titration of the agents resulted in amelioration of the acidaemia, suggesting a causal relationship between the infusions and the electrolyte imbalance. However, both patients eventually succumbed to cardiovascular decompensation in the context of electrolyte imbalance, although, as previously discussed, a contribution of the direct myocardial depressant effect of ketamine cannot be excluded.
An association between high-dose, continuous ketamine and a metabolic acidosis was first described in a 1974 case report on malignant hyperthermia 76 . A three-yearold girl undergoing general anaesthesia received a bolus of 2 mg/kg of ketamine followed by repeated injections of 1 mg/kg of ketamine throughout a 40-minute operation. Postoperative blood tests showed a severe non-anion gap metabolic acidosis that was corrected with sodium bicarbonate. Similarly, midazolam infusion (12 mg/kg/hour) for SE has been associated with a hyperchloraemic nonanion gap metabolic acidosis that resolved within five hours of discontinuing midazolam treatment 77 . Both midazolam and ketamine are prepared with hydrochloric acid to achieve appropriate solubility 78,79. In fact, midazolam initially became a preferred agent for sedation because its solvent is hydrochloric acid and not the known toxic agent, propylene glycol. Hydrochloric acid toxicity is likely a cumulative effect, since all relevant case reports, inclusive of our findings, report electrolyte dysregulation starting two to six days after initiating continuous infusions.
In retrospect, we suspect that in Case 1, hydrochloric acid toxicity from ketamine and midazolam infusions directly contributed to the patient's hyperchloraemic non-anion gap acidosis, and that topiramate-induced renal tubular acidosis may have played a lesser role. In Case 2, however, an additional complication of a high anion gap acidosis (with only a mildly elevated lactate) requires further explanation. Benzyl alcohol is another agent regularly used as a preservative in midazolam, propofol, and phenobarbitone, as well as in some formulations of injectable ketamine 80 . Benzyl alcohol toxicity as a consequence of cumulative dosing was first described in the 1980s in neonates exposed to multiple injections with benzyl alcohol-preserved catheter flushes and reconstituted medications 81, 82 . The clinical syndrome of benzyl alcohol toxicity comprises an anion gap metabolic acidosis, central nervous system depression, renal failure, seizure, and cardiovascular collapse 83 . While threshold doses for toxicity are not well-defined, it is possible that accumulation of benzyl alcohol through propofol and midazolam administration, in addition to the effect of cumulative hydrochloric acid administration, contributed to our patient's decompensation in Case 2.
Of note, only one study reviewed cited an increase in liver function tests related to ketamine infusion, and this effect was both transient and in paediatric patients 57 . However, across the addiction literature and, more recently, the chronic pain literature, there have been several reports of ketamineinduced cholestasis and hepatotoxicity [84] [85] [86] . One of the largest reviews of ketamine abuse patients from Hong Kong showed that 16.3% of 178 patients who presented to a poison centre (and had liver function testing) had evidence of liver injury 87 . Numerous case reports of chronic ketamine abusers support this trend and furthermore suggest that the nature of the liver injury is related to chronic dilation of the biliary tree and obstructive jaundice through NMDA-mediated effects on smooth muscle tone (in addition to a possible component of direct ketamine-induced hepatotoxicity by an undetermined mechanism) 88, 89 . Interestingly, in the canonical 2011 study by Noppers et al discussing ketamine-induced liver injury in the chronic pain literature, investigators stopped their treatment protocol prematurely in the face of elevated liver function tests 84 . Noppers et al acknowledge that some patients may have been taking other medications that would have additionally affected liver function, and further review of the chronic pain literature yields evidence that the effect of ketamine on liver enzymes is likely transient, or at least, reversible. For example, 16 out of 20 patients in a phase II study of five-day ketamine infusion for complex regional pain syndrome experienced elevations in liver function tests that returned to baseline within ten to 14 days 90 . It is likely that the more permanent effects of ketamine on the hepatobiliary system are related to a chronic, lifelong pharmacologic insult. However, given that the doses of ketamine warranted in RSE are both high and administered over an extended period, pre-treatment and serial liver function testing during treatment, particularly in patients with a history of liver dysfunction or taking concomitant medications with known hepatotoxicity, should be considered in RSE treatment protocols.
Limitations
Overall, despite yielding insightful inferences on ketamine's efficacy and related adverse effects in RSE, our review has significant limitations. First, the number of studies identified (21) is limited and a large number (90%) of these studies are case reports and case series with small sample sizes, which reduces the generalisability of our study. Additionally, the inherently low-impact nature of the data makes it difficult to perform meaningful meta-analysis. The heterogeneity of the treatment protocols used across studies also limits our ability to suggest a standard ketamine dosing strategy for either adult or paediatric RSE patients. Perhaps the greatest confounder is the use of polypharmacy across studies, inclusive of our case reports. Given the large number of medications all patients received concomitantly with ketamine, it is possible that seizure cessation may have been related to a cumulative or delayed effect of the co-administered or previously administered medications. Lastly, two studies reviewed in both the paediatric and adult analysis did not differentiate data between adult and paediatric patients, and all corresponding data was therefore reviewed in both groups, possibly skewing our interpretation 47, 50 . Nevertheless, despite these limitations, this review successfully compiles current ketamine use patterns, documents ketamine's rapid efficacy in treating RSE, and creates incentive for planning higher-powered studies to investigate possible consequences of long-term infusion. Additionally, to our knowledge, this is the first systematic review of ketamine use in seizure that examines the incidence and scope of associated adverse events including those related to co-administration with more frequently used agents such as midazolam.
Conclusions
The bulk of the literature on ketamine use in RSE demonstrates that ketamine is effective in achieving prompt cessation of seizure activity. Better clinical outcomes are achieved with earlier administration of ketamine within the SE treatment protocol and our review potentially supports the use of ketamine earlier in any SE treatment algorithm. Ketamine's efficacy is reinforced by a multitude of animal and molecular studies demonstrating the utility of NMDA receptor antagonism in RSE treatment in the context of the molecular, genetic and neuroplastic effects of prolonged seizure on the brain. However, further examination of the cumulative effects of ketamine (or ketamine and midazolam) administration and the risk of metabolic acidosis is required to clarify the safety profile and appropriate dosing schedule for these infusions. Additionally, the extent to which a patient is critically ill and would therefore predominantly experience the depressive cardiac effects of ketamine should be considered in any dosing protocol to avoid cardiovascular failure.
